Compare MakeMyTrip Ltd (MMYT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs GeneDx Holdings Corp — how do they compare? MakeMyTrip Ltd trades at $49.84 (market cap $5.07B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: MakeMyTrip Ltd is the larger of the two by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals.
| MMYT | WGS | |
|---|---|---|
Market Cap | $5.07B | $2.56B |
Sector | Technology | Technology |
52-Week High | $101.86 | $167.51 |
52-Week Low | $36.30 | $34.51 |
Enterprise Value | $5.73B | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MakeMyTrip (MMYT) trades at $53.90, down 3.09% today, showing technical bearish signals despite strong analyst support with 8 buy ratings. The company maintains solid revenue growth with $978M in 2025 revenue and $95M net income, though earnings volatility persists with mixed quarterly results. Recent news highlights institutional selling pressure despite positive industry outlook for internet delivery services.
Investment outlook remains cautiously optimistic given the 34% upside potential from analyst targets, but risks include declining cash flow trends and rising debt-to-asset ratios from 12% to 80% projected for 2026. The stock's high P/E ratio of 234 requires sustained earnings growth to justify valuation, making execution critical for future performance.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
